The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies

Metabolites. 2022 Jun 14;12(6):541. doi: 10.3390/metabo12060541.

Abstract

Abnormal blood coagulation or coagulopathy is a common manifestation of many pathological conditions. It occurs when there is an imbalance between the activities of the coagulation system and the fibrinolytic system, leading to excessive or impaired intravascular blood clot formation, which can disturb blood flow causing ischemia or hemorrhage in the affected tissues. A growing body of evidence has demonstrated blood coagulation abnormalities in association with cannabinoid use, suggesting the involvement of the endogenous cannabinoid system (ECS) in modulating blood coagulation. However, the evidence in the literature has been controversial on whether cannabinoids promote or inhibit blood coagulation. The ECS has been extensively studied in recent years for its potential as a therapeutic target for many diseases. This review provides a brief introduction to the ECS and discusses the reported anticoagulatory and procoagulatory effects of various cannabinoids, highlighting some possible mechanisms that might underlie the observed effects. Understanding the coagulatory effects of cannabinoids and the interaction between the coagulation system and the ECS is vital for developing novel therapeutics for coagulopathies.

Keywords: blood coagulation; cannabinoids; cannabis; coagulopathy; endocannabinoid system; endocannabinoids; hemorrhage; marijuana; thrombosis.

Publication types

  • Review

Grants and funding

This research received no external funding.